Through the merger agreement, Auris paid $4 per share in cash, which the company said is approximately 39.9% over the closing sale price of the common stock of Hansen Medical as reported in April.
The merger became official yesterday, making Hansen a wholly-owned subsidiary of the stealthy Auris, according to an SEC filing from Hansen Medical.
Current Auris CEO Fred Moll founded Hansen Medical in 2002 with an eye toward the intravascular space. Moll, a serial entrepreneur, also co-founded Mako Surgical, acquired in 2013 by Stryker Corp. and Restoration Robotics and its Artas hair restoration platform.
Former Hansen CEO Cary Vance and CFO Cristopher Lowe resigned as officers of the company with the merger, putting Moll back in corner office of the company he originally founded.
Mountain View, Calif.-based Hansen has a pair of platforms on the market: The Sensei system for electrophysiology procedures and the Magellan system for peripheral vascular interventions.
Redwood City, Calif.-based Auris is developing a surgical robot for ophthalmological procedures, but has not released any details surrounding the device. The acquisition will put 3 different robotic systems under Auris’ control.
As part of the deal, certain significant Hansen Medical stockholders said they will invest approximately $49 million into Auris upon the closing of the transaction.
The deal was originally announced in April.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.